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Background: Current therapy for relieving bronchoconstriction may be ineffective in severe asthma, particularly in
the small airways. The aim of this study was to further characterise responses to the recently identified novel
bronchodilators rosiglitazone (RGZ) and chloroquine (CQ) under conditions where β-adrenoceptor agonist efficacy
was limited or impaired in mouse small airways within lung slices.
Methods: Relaxation to RGZ and CQ was assessed following submaximal methacholine (MCh) pre-contraction, in
slices treated overnight with either RGZ, CQ or albuterol (ALB) (to induce β-adrenoceptor desensitization), and in
slices treated with caffeine/ryanodine in which contraction is associated with increases in Ca2+ sensitivity in the
absence of contractile agonist-induced Ca2+ oscillations. Furthermore, the effects of RGZ, CQ, ALB and isoproterenol
(ISO) on the initiation and development of methacholine-induced contraction were also compared.
Results: RGZ and CQ, but not ALB or ISO, elicited complete relaxation with increasing MCh pre-contraction and
maintained their potency and efficacy following β-adrenoceptor desensitization. RGZ, CQ and ALB maintained
efficacy following overnight incubation with RGZ or CQ. Relaxation responses to all dilators were generally
maintained but delayed after caffeine/ryanodine. Pre-treatment with RGZ, but not CQ, ALB or ISO, reduced MCh
potency.
Conclusions: This study demonstrates the superior effectiveness of RGZ in comparison to CQ and β-adrenoceptor
agonists as a dilator of mouse small airways. Further investigation of the mechanisms underlying the relatively
greater efficacy of RGZ under these conditions are warranted and should be extended to include studies in human
asthmatic airways.
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There is an unmet need for novel dilators for the treat-
ment of severe asthma, when current therapeutic agents,
such as the short acting β-adrenoceptor agonist albute-
rol (ALB), and long acting β-adrenoceptor agonists in
combination with anti-inflammatory glucocorticoids, are
ineffective at completely reversing symptoms [1,2].
The peroxisome proliferator-activated receptor γ (PPARγ)
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unless otherwise stated.(TAS2R) agonists, such as chloroquine have both been re-
cently identified as potential novel therapeutics for asthma
[3-6]. PPARγ has been implicated in lung disease and the
regulation of both inflammation and airway smooth
muscle function [5], and its expression is upregulated in
airways of asthmatic patients [7]. We have recently cha-
racterised novel PPARγ-independent dilator actions of
RGZ in mouse lung slices, which are independent of
K+-channel activation [6]. TAS2R agonists have also been
shown to elicit relaxation of both large airways, potentially
via large conductance Ca2+-activated K+-channels [4], and
human and mouse small airways as measured in lungal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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are upregulated in leukocytes from severe asthmatics [10].
The limitations of current dilator agents in severe asthma
may be due to their inability to overcome the increased
contraction associated with airway hyperresponsiveness, or
because of a loss of sensitivity due to β-adrenoceptor
desensitization and/or the development of tolerance with
chronic use [11,12]. The contribution of small intra-
pulmonary airways to this loss of dilator responsiveness is
relatively understudied [13-15]. Small airways have in-
creased sensitivity to contractile agents [16] and decreased
responsiveness to β2-adrenoceptor agonists relative to
larger airways [17]. Critical to this study, homologous
desensitization has been demonstrated in small airways by
culturing lung slices with high concentrations of short- or
long-acting β2-adrenoceptor agonists [18,19]. The major
aim of this study was to compare the efficacy of RGZ and
CQ under conditions of both increased contraction and
β-adrenoceptor desensitization.
The current study highlights the potential benefits of
RGZ and CQ as novel bronchodilators for the treatment
of asthma. Although less potent than ALB and iso-
proterenol (ISO) in mouse small airways, both RGZ and
CQ elicited complete relaxation under conditions of im-
paired β-adrenoceptor agonist responsiveness. Both ago-
nists maintained efficacy following overnight incubation
with their respective agonist. Despite similar potency in
mediating relaxation, the mechanisms of action of RGZ
and CQ were distinguished by the finding that only RGZ
could inhibit the initiation and development of airway
contraction resulting in a marked loss of MCh potency.
Methods
Animals
All experimental procedures in mice were approved by the
Animal Ethics Committees of the University of Melbourne
(approval #1011608 and #1212485). Male Balb/C mice
(6–12 weeks) were obtained from Animal Resources
Centre, Western Australia, and housed in the Biomedical
Sciences Animal Facility, University of Melbourne. Mice
were caged at 22°C under a normal 12:12 h light:dark
cycle, and given free access to a normal diet and tap water.
Mice were sacrificed by an intraperitoneal injection of
sodium pentobarbitone (0.40 ml, 60 mg ml−1, Cenvet
Australia).
Preparation of mouse lung slices
Lung slices were prepared by methods previously de-
scribed [20,21]. Briefly, lungs were inflated via a tracheal
cannula (20G Intima, Becton Dickinson) with warm
2% w/v ultra pure low melting point agarose (Invitrogen)
in Hank’s Balanced Salt Solution supplemented with
40 mM HEPES (sHBSS) then followed by a small bolus of
air. The agarose was solidified for 20 min at 4°C. A singlelobe was isolated and mounted in a vibratome in cold
sHBSS (VT 1000S, Leica Microsystems). 150μm thick sec-
tions were cut commencing at the lung periphery. Slices
were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 1% penicillin-streptomycin
solution, maintained at 37°C with 5% CO2.In vitro incubations for assessment of desensitization
Slices were incubated overnight with ALB (100 μM, Sigma-
Aldrich Australia) to induce β-adrenoceptor desensitization,
or with vehicle (water 0.1%). This concentration of ALB has
been previously shown to induce β2-adrenoceptor desen-
sitization in human small airways [18,19]. After incubation,
airways were pre-contracted with MCh (100 nM) prior to
measurement of dilator responses to ALB, ISO (Sigma-
Aldrich Australia), CQ (Sigma-Aldrich Australia) or RGZ
(Sapphire Bioscience Australia).
Separate slices were incubated overnight in CQ (100 μM)
or water (0.1%), or RGZ (100 μM) or DMSO (0.1%). Fol-
lowing incubation, slices were pre-contracted with 100 nM
MCh prior to measurement of dilator responses to CQ,
RGZ or ALB.Acquisition of small airway images
Lung slice images were captured using phase contrast mi-
croscopy on an inverted microscope (Eclipse Ti-U; Nikon)
with a CCD camera (model TM-62EX; Pulnix). Individual
slices were placed between two cover glasses on a custom-
made perfusion chamber (~100μL volume) after being
covered in a fine wire mesh (Small Parts Inc.) with a small
hole cut over a single airway (100–300 μm). Airways were
selected for experimentation based on the presence of an
intact layer of epithelial cells displaying ciliary activity and
reactivity to MCh.Measurement of airway reactivity
Lung slices were perfused with sHBSS or varying con-
centrations of agonists at a constant rate using a gravity-
fed perfusion system.
Some slices were treated with 20 mM caffeine and
50μM ryanodine to deplete intracellular Ca2+ stores and
lock ryanodine receptors in an open state [20,22]. This
abolishes Ca2+ oscillations and allows for assessment of
reactivity under conditions whereby subsequent airway
contraction and relaxation is due to changes in Ca2+
sensitivity only.
Some airways were pre-contracted with MCh prior to
perfusion in the presence of K+ channel inhibitors alone
(tetraethylammonium (TEA), glibenclamide, apamin,
charybdotoxin), followed by inhibitor and chloroquine
(10 μM). Inhibitor concentrations used were based on
previous studies [6,23].
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All digital images were recorded in time lapse (0.5Hz) and
analysed using image acquisition software (Video Savant;
IO Industries, Inc.). A grey scale threshold was chosen to
distinguish between the airway lumen and the surround-
ing tissue, with lumen area in each image calculated by
pixel summation.
Statistical analysis
Raw data for the airway lumen area in pixels was
normalized to the initial area to correct for minor differ-
ences between airway sizes. Time course data was deter-
mined from each individual frame collected at 2 s
intervals. Average constrictor and dilator responses
were obtained over the last minute of each perfusion
condition.
All data were expressed as mean±SEM, where each n
represents a single airway per mouse. Measures of aver-
age potency (pEC50) and maximum responses obtained
from fitted individual curves were compared by unpaired
t-tests. p < 0.05 was accepted as being statistically signifi-
cant. Statistical analysis was carried out using Graph Pad
Prism™ (version 5.0).
Results
RGZ and CQ have greater efficacy than β-adrenoceptor
agonists
We assessed the relative potency and efficacy of RGZ and
CQ in mouse small airways, comparing the effects of
cumulative versus sequential perfusion. A representative
trace from an airway pre-contracted with a singleFigure 1 Rosiglitazone and chloroquine elicit concentration-depende
slices were pre-contracted with 100 nM methacholine (MCh), prior to perfusio
showing changes in airway lumen area during A) cumulative perfusion and B
and RGZ (n = 4/group) added cumulatively or sequentially. Responses (mean
averaged over the last minute of perfusion at each dilator concentration.submaximal concentration of MCh (100 nM) shows that
increasing concentrations of CQ elicit complete relaxation
(Figure 1A). We have previously published a trace show-
ing that continuous perfusion with RGZ also completely
reverses a submaximal contraction to MCh [6]. Similar re-
sults were obtained when repeated pre-contractions with
MCh and sequential addition of increasing CQ or RGZ
concentrations were separated by washout periods, de-
monstrating reversibility and no acute desensitization for
both dilators (Figure 1B, 1C, 1D). Under the current ex-
perimental conditions, both CQ and RGZ had similar po-
tency and efficacy (Figure 1C, 1D).
In airways pre-contracted to a similar extent (Figure 2A),
cumulative concentration-response curves to RGZ and
CQ were compared with those for the β-adrenoceptor ag-
onists ALB and ISO (Figure 2B). RGZ and CQ had similar
potency and caused complete relaxation at the maximal
concentrations tested (% relaxation to 100 μM CQ: 105 ±
3%, 100 μM RGZ 107 ± 9%). Although ALB and ISO were
relatively more potent (pEC50; ISO: 7.9 ± 0.2), neither of
the β-adrenoceptor agonists fully reversed the MCh-
mediated contraction (Figure 2B). Saccharin, an agonist of
the bitter taste receptors, only produced partial relaxation
(22.9 ± 7.2%) at very high μM concentrations.
Relaxation to RGZ and CQ, but not β-adrenoceptor
agonists, is maintained with increased levels of MCh
pre-contraction
Maximally effective concentrations of each bronchodilator
(established in Figure 2) were used to assess their relative
abilities to overcome a greater level of pre-contraction,nt relaxation in mouse small airways in lung slices. Airways in lung
n with chloroquine (CQ) or rosiglitazone (RGZ). Representative traces
) sequential additions of CQ. C) D) Grouped data for CQ (n = 4/group)
± S.E.M) represent the% relaxation of the pre-contraction to MCh,
Figure 2 Rosiglitazone and chloroquine, but not isoproterenol, albuterol or saccharin, elicit full relaxation of mouse small airways in
lung slices. Airways were A) pre-contracted with 100 nM methacholine (MCh) to achieve ~25% reduction in lumen area over 5 min prior to
B) cumulative additions of albuterol (ALB, n = 9), isoproterenol (ISO, n = 7), rosiglitazone (RGZ, n = 4), chloroquine (CQ, n = 6) or saccharin (SACC,
n = 4) at 5 min intervals. Responses (mean ± S.E.M) represent A) the reduction in lumen area to MCh and B) the% relaxation of this pre-contraction
averaged over the last minute of each perfusion.
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nM MCh. Complete relaxation to both CQ and RGZ was
maintained (Figure 3A, 3B), but the partial relaxation in
response to both ISO and ALB was reduced against 300
nM MCh (Figure 3C, 3D). The time of onset of all bron-
chodilator responses was unchanged at the differing levels
of MCh-induced contraction.Figure 3 Rosiglitazone and chloroquine and, but not isoproterenol an
methacholine. Airways in lung slices were pre-contracted with 100nM me
A) chloroquine (CQ, 100 μM, n = 4, 8), B) rosiglitazone (RGZ, 100 μM, n = 3,
n = 4, 4). Responses (mean ± S.E.M) represent the average airway lumen are
over 5 min.Pre-treatment with RGZ, but not CQ or β-adrenoceptor
agonists, reduces MCh potency
To extend these observations, we then assessed the ability
of these dilators to inhibit the initiation and development
of MCh-induced contractions, using concentrations of
RGZ and CQ shown to relax pre-contracted airways. Fol-
lowing perfusion in the presence of CQ, RGZ, ALB ord albuterol, can overcome increased contraction to
thacholine (MCh) or 300nM MCh, prior to 5 min perfusion with
4), C) isoproterenol (ISO, 10 μM, n = 3, 4) or D) albuterol (ALB, 10 μM,
a (normalized to the initial area), measured at 2 sec intervals
Donovan et al. Respiratory Research 2014, 15:29 Page 5 of 12
http://respiratory-research.com/content/15/1/29ISO, airways were exposed to increasing concentrations
of MCh (Figure 4). There was a decrease in MCh po-
tency in the presence of 10 μM CQ (MCh pEC50: vehicle
6.9 ± 0.1; +10 μM CQ 6.3 ± 0.1, p < 0.05), but this was
not further reduced with 100 μM CQ (Figure 4A). The
presence of both 30 μM and 100 μM RGZ significantly
decreased the potency of MCh (MCh pEC50: vehicle 7.4 ±
0.1, +30μM RGZ 6.6 ± 0.0, p < 0.05) (Figure 4B). 100 μM
RGZ also decreased the maximum contraction to MCh
(Figure 4B). Neither ISO nor ALB reduced the potency of
MCh or the maximum reduction in airway lumen area
(MCh pEC50: control 7.3 ± 0.05, +10 μM ALB 7.4 ± 0.17,
NS) (Figure 4C, 4D).
RGZ and CQ, but not β-adrenoceptor agonists, are resistant
to desensitization
To compare whether dilator responses to RGZ, like CQ,
were resistant to heterologous desensitization, lung slices
were incubated overnight with ALB (100 μM). Under
these conditions, β-adrenoceptor-mediated relaxation to
ALB was completely abolished (Figure 5A, 5B, 5D), and
relaxation to ISO (10 μM) was also significantly reduced
(maximum relaxation after vehicle o/n: 54.0 ± 7.0%, after
ALB o/n: 11.7 ± 6.7%, p < 0.05). Despite β-adrenoceptor
desensitization, concentration-dependent relaxation to
both CQ and RGZ was maintained with similar potency
and maximum (Figure 5A, 5C, 5E).Figure 4 Rosiglitazone, but not chloroquine, isoproterenol or albuter
induced contraction. Lung slices were perfused with increasing concentrati
(control: n = 8, 10 μM: n = 8, 100 μM: n = 3), B) rosiglitazone (RGZ) (vehicle: n =
(control: n = 4, 10 μM: n = 4) or D) albuterol (ALB) (control n = 4, 10 μM, n = 4
to the initial area), averaged over the last minute of perfusion at each MCh coTo determine whether relaxation to RGZ or CQ was im-
paired following overnight incubation with the same dila-
tor, slices were incubated with 100 μM of either agonist or
appropriate vehicles. Both RGZ and CQ elicited similar re-
laxation following these overnight incubations (Figure 6A,
6B). Relaxation to ALB (10 μM) was also maintained irre-
spective of the incubation conditions (Figure 6A, 6B).
All dilators elicit delayed relaxation in caffeine/Ryanodine
treated slices
To compare the capacity of RGZ and CQ to overcome
small airway contraction due to Ca2+-sensitivity alone,
reactivity was assessed after treatment with caffeine
(20 mM)/ryanodine (50 μM) to induce a transient con-
traction and to lock ryanodine receptors in an open
state to clamping intracellular Ca2+ levels. Subsequent
exposure to caffeine did not cause contraction, confir-
ming that subsequent responses could be attributed to
altered calcium sensitivity alone (Figure 7A, 7B).
Relaxation responses to a single concentration of CQ or
RGZ were relatively slower after caffeine/ryanodine treat-
ment such that a plateau response was not achieved within
5 min (Figure 7A, 7C, 7D). The average relaxation response
measured over the final minute of the perfusion was slightly
reduced for both dilators (RGZ control: 86.1 ± 1.1%,
post caffeine/ryanodine: 70.4 ± 2.9%, p < 0.05, Figure 7D).
However, relaxation to CQ and RGZ (Figure 7C, 7D) wasol, inhibits the initiation and development of methacholine-
ons of methacholine (MCh) in the presence of A) chloroquine (CQ)
4, 10 μM: n = 3, 30 μM: n = 4, 100 μM: n = 4), C) isoproterenol (ISO)
). Responses (mean ± S.E.M) represent the airway lumen area (normalized
ncentration. *p < 0.05, 2 way ANOVA, Bonferroni post-hoc.
Figure 5 Rosiglitazone and chloroquine maintain potency and efficacy despite β-adrenoceptor desensitization. Slices were incubated
overnight with vehicle (0.1% water) or albuterol (ALB, 100 μM). Airways were then pre-contracted with 100 nM methacholine (MCh) prior to
addition of 10 μM ALB and concentration response curves to rosiglitazone (RGZ) or chloroquine (CQ). A) Representative traces illustrating RGZ
concentration-response curves following overnight incubation with vehicle or ALB. Relaxation responses to B) C) 10 μM ALB and CQ (n = 4/group)
and D) E) 10 μM ALB and RGZ (n = 4/group) following overnight incubation with vehicle or 100 μM ALB. *p < 0.05, unpaired t-test.
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Figure 6 Rosiglitazone and chloroquine maintain efficacy following overnight incubation with CQ or RGZ. Slices were incubated overnight
with vehicle (0.1% water for chloroquine (CQ), 0.1% DMSO for rosiglitazone (RGZ)) or CQ (100 μM) or RGZ (100 μM). Airways were pre-contracted with
100 nM methacholine (MCh) prior to addition of albuterol (ALB, 10 μM) or CQ (100 μM) or RGZ (100 μM). A) Relaxation response to ALB and RGZ
following overnight incubation with RGZ (n = 3/group). B) Relaxation response to ALB and CQ following CQ incubation overnight (n = 3/group).
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7E, 7F).
Under control conditions, both β-adrenoceptor agonists
elicited rapid but only partial relaxation. After caffeine/
ryanodine treatment, the peak responses associated with
this rapid relaxation were lost but despite the delayed on-
set, both agonists elicited gradual relaxation of similar
magnitude to the control responses by the end of 5 min
perfusion (Figure 7B, 7E, 7F).
Time-control experiments established that there was no
difference between the first and second exposure to any
agonist tested, indicating that the impairment of relaxa-
tion to all agonists tested was due to caffeine/ryanodine
treatment and not acute desensitization caused by the ini-
tial 5 min exposure period (data not shown).
CQ-mediated relaxation is inhibited by TEA but not by
selective K+-channel inhibitors
Given conflicting reports in the recent literature of the
mechanism underlying CQ-mediated relaxation, responses
to CQ in small airways were compared in the absence or
presence of various K+-channel inhibitors (Table 1). The
non-selective K+-channel inhibitor TEA alone partially re-
versed the reduction in lumen area in the presence of
MCh, and subsequent relaxation in response to perfusion
with CQ in the continued presence of TEA was impaired.
In contrast, TEA had previously been shown to have no
effect on relaxation to RGZ in mouse lung slices [6].
Assessment of the effects of more selective inhibitors of
K+-channels on CQ-mediated relaxation was undertaken.
Neither the ATP-sensitive K+-channel inhibitor, gliben-
clamide, the small conductance Ca2+-activated K+-channel
inhibitor apamin, nor the high conductance Ca2+-acti-
vated K+-channel inhibitor, charybdotoxin alone altered
the contractile response to MCh, and full relaxation to
CQ was maintained.
Discussion
In the present study, we have extended previous studies
exploring responses to RGZ and CQ in small airways in
mouse lung slices [6,9], to further characterize their rela-
tive therapeutic potential to oppose airway constrictionin asthma. We confirmed that these dilators were less
potent than β-adrenoceptor agonists [4,6], but unlike ALB
and ISO, both RGZ and CQ were able to elicit complete re-
laxation at μM concentrations, even with increasing levels
of MCh-induced pre-contraction. Critically, we have now
demonstrated that both RGZ and CQ maintain their effi-
cacy under conditions of β-adrenoceptor desensitization,
with neither dilator causing homologous desensitization
or reducing the sensitivity of mouse small airways to
β-adrenoceptor agonists. However, only RGZ was able to
inhibit the initiation and development of maximal MCh-
induced contraction, suggesting additional potential bene-
fit over CQ as a novel dilator for the treatment of asthma.
Current therapeutic approaches to relieve asthma symp-
toms with inhaled β-adrenoceptor agonists are generally
effective, however, a significant proportion of patients have
poorly controlled asthma [2,24]. It is for this group of pa-
tients that alternative or supplementary dilator therapies
may provide benefit. We have assessed two distinct novel
bronchodilators in mouse small airways. RGZ, an agonist
for PPARγ, has been shown to elicit acute relaxation of
pre-contracted mouse trachea and small airways [6,25].
CQ, a bitter taste receptor agonist, has been shown to
activate TAS2R present on airway smooth muscle and
cause bronchodilation [4].
There has been increased recent interest in targeting the
small airways, a major site of airway obstruction in
difficult-to-treat patients. Both RGZ and CQ were able to
elicit relaxation at lower potency but higher efficacy than
the β-adrenoceptor agonists ISO and ALB in mouse small
airways. The relative potency of CQ compared with ISO in
small airways (>300-fold lower) is smaller than the 10,000-
fold difference reported previously in mouse trachea [4,26]
but remains consistent with the low affinity of TAS2Rs
compared to other GPCRs, such as the β-adrenoceptor.
We also found an additional TAS2R agonist, SACC to
be >100 fold less potent than CQ in the small airways. This
is in agreement with minimal response to SACC pre-
viously reported in human and mouse airways [9,27].
Since increasing levels of contraction are known to
decrease the efficacy of various dilators [6,28], we
assessed all four dilators at two levels of MCh-induced
Figure 7 (See legend on next page.)
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Figure 7 Rosiglitazone and chloroquine and oppose airway contraction due to calcium sensitivity. Small airways in lung slices were
pre-contracted with 300 nM methacholine (MCh), prior to perfusion with dilators for 5 min. Representative traces show changes in airway lumen
area for relaxation to A) chloroquine (CQ) and B) isoproterenol (ISO) before and after treatment with caffeine/ryanodine. Grouped data for C) CQ
(100 μM), D) rosiglitazone (RGZ, 100 μM), E) ISO (10 μM) and F) albuterol (ALB, 10 μM) (n = 4/group) show pre- and post-caffeine/ryanodine
responses within the same slice. Responses (mean ± S.E.M) represent the% relaxation of the MCh pre-contraction measured at 2 sec intervals
over 5 min.
Donovan et al. Respiratory Research 2014, 15:29 Page 9 of 12
http://respiratory-research.com/content/15/1/29contraction. While the β-adrenoceptor agonists were
susceptible to functional antagonism, both CQ and RGZ
were able to overcome a higher pre-contraction. This is
consistent with previous findings that CQ (100 μM) and
RGZ (100 μM) could elicit complete relaxation at up to
300 and 100 times higher concentrations of MCh respect-
ively [6,9].
To extend this observation, we also examined the ability
of each dilator to prevent the initiation and development
of MCh-induced contraction. While pre-treatment with
ISO and ALB had no significant effect on the MCh
concentration- response curve, both CQ and RGZ were
able to inhibit the reduction in airway area at low MCh
concentrations. However only RGZ, but not CQ, reduced
both MCh potency and the maximum contraction. This
finding in the mouse contrasts with guinea pig trachea
where pre-incubation with CQ, at a supramaximal con-
centration of 300 mM, inhibited the development airway
contraction to several contractile mediators, including car-
bachol [29].
Desensitization of GPCRs may limit the therapeutic effi-
cacy of agonists by rapidly attenuating the early signaling
that leads to the cellular response. A reduction of bron-
chodilator efficacy due to β-adrenoceptor desensitization
is a well-recognized limitation of β-adrenoceptor agonists
[30,31]. Given this background, we assessed whether se-
quentially or cumulative administration of CQ or RGZ
would influence their efficacy in mouse small airways. Our
experimental traces suggested that increasing concentra-
tions of CQ induced rapid initial peak dilator response
that could not be maintained. However, its similar potencyTable 1 The effect of potassium channel inhibitors on
chloroquine-mediated relaxation of mouse small airways
n % Relaxation
Inhibitor alone Inhibitor + CQ
Vehicle 8 1.2 ± 2.1 88.1 ± 4.9
TEA (1 mM) 4 36.3 ± 7.8*** 39.8 ± 3.2^^^
Glibenclamide (1 μM) 4 0.6 ± 2.4 89.3 ± 2.9
Apamin (500 nM) 4 0.1 ± 2.5 92.8 ± 3.7
Charybdotoxin (10 nM) 4 5.2 ± 2.1 83.4 ± 11.1
Airways were pre-contracted with 100nM MCh prior to perfusion for 5 min in
the presence of inhibitor alone, followed by inhibitor and chloroquine (10 μM).
Responses (mean ± S.E.M) represent the% relaxation of the pre-contraction to
MCh, averaged over the last minute of perfusion. ***p < 0.0001 cf vehicle.
^^^p < 0.0001 cf CQ alone.and efficacy in cumulative concentration-response curves
suggests that the relaxation to higher concentrations of
CQ was not limited by acute receptor desensitization.
Similar findings with RGZ illustrate that both dilators are
reversible even at the highest concentrations tested.
Recent reports have suggested that CQ promotes hom-
ologous desensitization of human airway smooth muscle
TAS2Rs occurring as early as 5 min after exposure to
quinine and becoming progressively greater with longer
incubation times [32]. Given that we did not see any acute
desensitization to either CQ or RGZ, we assessed whether
overnight incubation at high concentrations would induce
either homologous desensitization or heterologous desen-
sitization to ALB. We found no evidence of impaired re-
laxation to either dilator and are the first to demonstrate
no heterologous desensitization of the β-adrenoceptor, as
seen by the maintained response to ALB.
These findings may indicate that the TAS2R subtypes
present on mouse airway smooth muscle may not be
prone to desensitization via the G-protein-coupled recep-
tor kinase (GRK) as previously suggested in human airway
smooth muscle cells [32,33]. It does provide crucial evi-
dence that RGZ and CQ do not cross-desensitize the
β-adrenoceptor and that future combination therapy with
these dilators and β-adrenoceptor agonists in current use
is viable.
Homologous β-adrenoceptor desensitization was also
established in lung slices following persistent exposure to
ALB. Treatment with ALB almost completely abolished
subsequent ALB-mediated relaxation in mouse small air-
ways. The response to the β1/β2-adrenoceptor agonist ISO
was only partially inhibited, consistent with the contribu-
tion of β1-adrenoceptors to mouse airway relaxation [34].
This is the first study to show that RGZ and CQ can
maintain potency and complete small airway relaxation
following β-adrenoceptor desensitization in mouse lung
slices. The finding is consistent with previous results ob-
tained with CQ in mouse trachea and human precision
cut lung slices following 18 h incubation with ISO or the
long acting β-adrenoceptor agonist salmeterol respectively
[8]. The ability of both RGZ and CQ to cause relaxation
under conditions of β-adrenoceptor desensitization pro-
vides further evidence that these dilators are working via a
different mechanism to β-adrenoceptor agonists.
We explored another potential mechanism downstream
of the β-adrenoceptor itself that could contribute to RGZ-
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relaxation to both short-acting β-adrenoceptor agonists
and RGZ is associated with inhibition of MCh-induced
increases in both Ca2+-oscillations and Ca2+-sensitivity
[6,35]. We compared the effects of CQ with RGZ, ISO
and ALB after caffeine/ryanodine treatment to assess
whether relaxation to CQ could also be maintained when
the contraction to MCh was due to Ca2+-sensitivity alone.
CQ and RGZ appeared to be slightly less effective at
reversing MCh pre-contraction than under control con-
ditions, while there was a notable loss of the rapid phase
of the β-adrenoceptor-mediated relaxation. The slower
rate of relaxation to CQ and RGZ after caffeine/ryanodine
treatment suggests that a longer perfusion period with
either dilator might be necessary to determine whether it
can fully overcome the increase in Ca2+-sensitivity in
response to MCh. However these novel dilators main-
tained their greater efficacy than ISO or ALB under these
conditions.
Consideration of the potential contribution of the regu-
lation of Ca2+-sensitivity by CQ was important, as this had
not been addressed in the initial study describing dilator
responses to bitter-taste compounds [4]. A paper pub-
lished during the preparation of this manuscript confirms
that bitter-taste compounds such as CQ reduce Ca2+ sen-
sitivity in mouse small airways, and also demonstrates that
CQ can inhibit agonist-induced Ca2+ oscillations when re-
versing bronchoconstriction [9]. As such, these findings
have yet to differentiate between the mechanisms of ac-
tion of CQ and RGZ, which also inhibits Ca2+signaling
and sensitivity [6].
There are conflicting reports of the contribution of
K+-channel activation to CQ-mediated relaxation. Al-
though BKCa-channels had initially been implicated in the
dilator response to TAS2R agonists in mouse trachea [4],
a subsequent report did not replicate this finding, with
relaxation to CQ maintained in the presence of iberioto-
xin or two other BKCa-channel-blockers, and currents
through BKCa-channels unaltered by CQ [36].
Our results obtained in mouse small airways showed
that the nonselective K+-channel inhibitor TEA alone
caused partial reversal of the MCh pre-contraction. This
may be a consequence of hyperpolarization of airway
smooth muscle by TEA, disturbing the balance of in- and
outwardly rectifying K+-currents regulating the resting
membrane potential [37]. Following this partial relaxation
to TEA, the subsequent relaxation by CQ in the presence
of TEA was almost completely abolished, suggesting that
this TAS2R agonist was at least partially dependent on
K+-channel activation for its relaxant effect in mouse
small airways.
Despite this finding, we were unable to implicate a spe-
cific K+-channel in CQ-mediated relaxation in mouse small
airways. Neither the ATP-sensitive K+-channel inhibitorglibenclamide, the small conductance Ca2+-activated
K+-channel inhibitor apamin nor the large conductance
and voltage-gated K+-channel inhibitor charybdotoxin af-
fected the MCh-induced stable contraction or relaxation to
CQ. Additional mechanisms mediating CQ-induced airway
relaxation are likely, with further studies required to assess
which K+-channels may be involved.
It is also possible that different mechanisms are impli-
cated depending on the preparation in which the actions
of CQ are assessed. Studies in isolated mouse airway
smooth muscle cells and isolated trachea showed that CQ
inhibited MCh-induced Ca2+ signaling and reversed con-
traction by blocking voltage-gated Ca2+ channels (VGCC)
via Gβγ or Gαi signaling [38]. However, in mouse small
airways in lung slices, VGCC do not play a major role in
MCh-mediated contraction [39]. In this setting, broncho-
dilation with bitter taste compounds was unaffected by
blockade of Gβγ or Gαi signaling, suggesting that it could
be directed by Gα-gustducin or other G-proteins known
to associate with TAS2R [9].
The results with CQ are in contrast to RGZ, as rela-
xation to RGZ has been shown to be maintained in the
presence of TEA [6]. The relative potential of these dila-
tors to provide relief for patients with difficult-to-treat
asthma may be informed by the previous clinical evidence
that K+-channels openers have had limited therapeutic
benefit in asthma treatment [40,41]. However, most of the
bronchodilators that activate K+-channels are also known
to exert other effects on airway smooth muscle, such as
decreasing Ca2+ sensitivity [42]. Nevertheless, the finding
that RGZ-mediated dilation is resistant to TEA but can
still overcome contraction due to Ca2+-sensitivity alone
[6], provides additional pre-clinical evidence to support its
potential benefit in asthma treatment.
Conclusion
Both RGZ and CQ, but not β-adrenoceptor agonists, were
able to elicit complete relaxation with similar potency in
mouse small airways, which was maintained under con-
ditions of homologous β2-adrenoceptor desensitization.
Although both RGZ and CQ could overcome contraction
due to calcium sensitivity alone, only RGZ inhibited the
initiation and development of a maximal contraction to
MCh. Further elucidation of their mechanisms of action is
warranted, to support their clinical assessment as novel
bronchodilators targeting small airways in patients with
poorly controlled asthma. Further investigation of the
mechanisms underlying the superior dilator responsive-
ness to RGZ in comparison to CQ and β-adrenoceptor ag-
onists under these conditions are warranted and should
be extended to human asthmatic airways.
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